Predictable CRISPR/Cas9-Mediated COL7A1 Reframing for Dystrophic Epidermolysis Bullosa. Kocher T, March OP, Bischof J, Liemberger B, et al. J Invest Dermatol 2020;140:1985-1993.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kocher T, March OP, Bischof J, Liemberger B, et al. Predictable CRISPR/Cas9-Mediated COL7A1 Reframing for Dystrophic Epidermolysis Bullosa. J Invest Dermatol 2020;140:1985-1993.
PMID: 32142798